Reports Q3 revenue $0, consensus $950,000. “Our recent license of SYN-2510 is a significant milestone for Instil, positioning us with a potentially best-in-class asset in one of the most significant areas of interest in oncology,” said Bronson Crouch, CEO of Instil. “As we continue to build our internal team to operationalize the clinical development of SYN-2510, we are excited for the progress ImmuneOnco continues to make in advancing the program in its China trials.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIL:
- Instil Bio initiated with a Market Perform at JMP Securities
- Baird positive on Instil Bio’s SYN-2510 development strategy
- Instil Bio Outlines Oncology Strategy and Collaborative Efforts
- Instil Bio price target raised to $120 from $40 at H.C. Wainwright
- Instil Bio, ImmuneOnco announce registrational strategy for SYN-2510/IMM2510
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue